All AbMole products are for research use only, cannot be used for human consumption.
Triptolide covalently binds to human XPB and inhibits its DNA-dependent ATPase activity, which leads to the inhibition of RNA polymerase II-mediated transcription and likely nucleotide excision repair.PG490 inhibits interleukin(IL)-2 expression by normal human peripheral blood lymphocytes stimulated with phorbol 12-myristate 13-acetate (PMA) and antibody to CD3 (IC50 of 10 ng/ml), and with PMA and ionomycin (Iono, IC50 of 40 ng/ml).PG490 inhibits the induction of DNA binding activity at the purine-box/antigen receptor response element (ARRE)/nuclear factor of activated T-cells (NF-AT) target sequence but not at the NF-kappaB site.PG490 also inhibits PMA-stimulated activation of a chimeric transcription factor in which the C-terminal TA1 transactivation domain of NF-kappaB p65 is fused to the DNA binding domain of GAL4. In 16HBE human bronchial epithelial cells, IL-8 expression is regulated predominantly by NF-kappaB, and PG490 but not cyclosporin A can completely inhibit expression of IL-8.PG490 potently inhibited TNF-alpha-induced activation of NF-kappaB. PG490 also blocked TNF-alpha-mediated induction of c-IAP2 (hiap-1) and c-IAP1 (hiap-2), members of the inhibitor of apoptosis (IAP) family. Interestingly, PG490 did not block DNA binding of NF-kappaB, but it blocked transactivation of NF-kappaB.
Transl Lung Cancer Res. 2021 Feb;10(2):1007-1019.
Triptolide inhibits epithelial-mesenchymal transition phenotype through the p70S6k/GSK3/β-catenin signaling pathway in taxol-resistant human lung adenocarcinoma
Triptolide purchased from AbMole
 |
Source | Transl Lung Cancer Res (2021). Figure 5. Triptolide (Abmole Bioscience, Houston, TX, USA) |
| Method | Tumor model in vivo | |
| Cell Lines | Male Bagg Albino (BALB)/c nude 6-week-old mice | |
| Concentrations | 0.4 mg/kg; 0.8 mg/kg | |
| Incubation Time | 24 d | |
| Results | The mean volumes of subcutaneous tumors in low-dose (0.4 mg/kg) and high-dose (0.8 mg/kg) triptolide groups were smaller than those in the vehicle group |
 |
Source | Transl Lung Cancer Res (2021). Figure 2. Triptolide (Abmole Bioscience, Houston, TX, USA) |
| Method | cell viability assay | |
| Cell Lines | The A549/TaxR cells | |
| Concentrations | 0, 20, 40, and 60 nM | |
| Incubation Time | 24 h | |
| Results | Additionally, as shown in Figure 3B, cell viability increased to 92% after triptolide treatment (20 nM, 24 hours). A549/TaxR cells remained viable after triptolide treatment (20 nM), apoptosis was induced (Figure 2E), and migration and invasion was inhibited. |
| Cell Experiment | |
|---|---|
| Cell lines | N2a and SKNSH cells |
| Preparation method | Cell viability determination Cells were seeded in serum-containing media onto 96-well plates at densities of 3 × 103 cells per well for N2a and 5 × 103 cells per well for SKNSH. Following overnight incubation, cells were treated with varying concentrations of triptolide in serum-free media and re-incubated for varying time courses at 37 °C. Controls were treated with serum-free media.Cell viability was determined using an MTT assay. Reagent was prepared by dissolving thiazolyl blue tetrazolium bromide (Sigma-Aldrich) in phosphate-buffered saline (Invitrogen) at a concentration of 2 mg/mL and filtering. After cells were incubated in 96-well plates and subsequently exposed to triptolide at varying doses and time durations, 20 μL MTT reagent were added to each well. Cells were re-incubated at 37°C for 4 hours, after which all liquid was aspirated from each well and absorbances were measured at 550 and 650 nm. These experiments were performed in triplicate and repeated 4 times. |
| Concentrations | 31.25 to 500 nM |
| Incubation time | 24 and 48 h |
| Animal Experiment | |
|---|---|
| Animal models | Female A/J mice bearing Orthotopic neuroblastoma model |
| Formulation | DMSO |
| Dosages | 0.4 mg/kg |
| Administration | intraperitoneal injections |
| Molecular Weight | 360.40 |
| Formula | C20H24O6 |
| CAS Number | 38748-32-2 |
| Solubility (25°C) | DMSO 25 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related NF-κB Products |
|---|
| DCZ5418
DCZ5418 is an inhibitor of TRIP13. |
| Ro 106-9920
Ro 106-9920 is a potent inhibitor of NF-kappaB. |
| MRS2693 trisodium
MRS2693 trisodium is a selective P2Y6 agonist with an EC50 value of 0.015 μM. |
| PTD-p65-P1 Peptide TFA
PTD-p65-P1 Peptide TFA is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis. |
| Narlumosbart
Narlumosbart is a human IgG4ҡ monoclonal antibody (mAb) that targets Receptor Activating Factor for Nuclear Factor κB Ligand (RANKL) and can be used in studies related to Giant Cell Tumor of Bone (GCTB). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
